Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax plus Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma
NCT06742996Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Mar 2025
- Primary completion
- Aug 2028
- Countries
- 17
01
Overview
A Phase 3 trial of sonrotoclax in mantle cell lymphoma (MCL), sponsored by BeOne Medicines. Started Mar 2025; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06742996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742996.